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ABSTRACT 
 Objective: Adrenal myelolipoma (AM) is a benign 
tumor composed of mature fat cells and hemopoietic 
elements. Most AMs are incidental findings on imaging 
and clinically asymptomatic. The purpose of this case 
report is to describe a rare case of AM and explore its clini-
cal manifestations, imaging features, and treatment. 
 Methods: In this study, we report a case of a rapidly 
growing right AM in a patient with uncontrolled hemoglo-
bin sickle cell disease. A 38-year-old male presented to our 
institution’s endocrine surgery clinic for evaluation of an 
enlarging right adrenal mass. This mass was incidentally 
found during an abdominal ultrasound performed for trans-
aminitis and thrombocytopenia. Patient was asymptomatic 
without any abdominal discomfort, back pain, nausea, 
or vomiting. 
 Results: Patient was lost to follow up until 2018. 
Follow-up computed tomography scan in 2018 showed the 
right adrenal mass measuring 12.3 cm in greatest dimen-
sion with significant macroscopic fat. Given the imaging 
features, AM was the presumed diagnosis. However, with 
a medical history of uncontrolled sickle cell disease, extra-
medullary hematopoiesis and rapidly growing liposarcoma 
could not be ruled out. Surgical excision was performed 
due to size and significant tumor growth. Diagnosis was 
confirmed with histopathology and revealed myelolipoma.
 Conclusion: Image characteristics can be helpful in 
diagnosis of AM; however, the appearance of this lesion 
on computed tomography can be similar to other adrenal 
gland pathologies such as liposarcoma and mass-forming 
extramedullary hematopoiesis. Percutaneous needle biopsy 
may be indicated if the diagnosis remains unclear. (AACE 
Clinical Case Rep. 2020;6:e54-e58)
Abbreviations:
AM = adrenal myelolipoma; CT = computed tomog-
raphy; EMH = extramedullary hematopoiesis; SCD = 
sickle cell disease
INTRODUCTION 
 With frequent use of imaging modalities, adrenal 
masses are routinely discovered after cross-sectional 
imaging. The differential diagnoses of adrenal inci-
dentalomas include myelolipoma, pheochromocytoma, 
congenital adrenal hyperplasia, adenoma, and carcinoma. 
Biochemical testing and follow-up imaging are commonly 
used to differentiate between these adrenal masses. Adrenal 
myelolipoma (AM) is the only adrenal tumor with pathog-
nomonic imaging features and can be diagnosed radio-
graphically. These benign adrenal carcinomas are managed 
conservatively and surgery is reserved for rapidly grow-
ing or symptomatic tumors (1). Here, we report a case of 
a giant fat-containing right adrenal mass in a patient with 
uncontrolled sickle cell disease (SCD). 
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 A 38-year-old man with a past medical history of type 
2 diabetes mellitus and hemoglobin SCD presented for 
initial evaluation to the endocrine surgery clinic in 2014. 
He was referred for evaluation of an incidentally discov-
ered right adrenal mass while undergoing an abdominal 
ultrasound performed for transaminitis and thrombocyto-
penia (Fig. 1). The patient was asymptomatic without any 
abdominal pain, weight gain, or symptoms attributable 
to mass effect. His only complaint was fatigue which he 
ascribed to his SCD. At this time, a biochemical profile 
including plasma metanephrines and low-dose dexametha-
sone suppression test were normal. Given the significant 
growth in size of the mass during the follow-up period, the 
patient was scheduled for surgery but was lost to follow up. 
He presented again to our clinic in 2018 to reestablish care 
and discuss surgery.
 Review of prior imaging studies performed for differ-
ent clinical indications showed the right adrenal mass 
measuring only 1 cm in 2001 and 4.4 cm in 2011 with 
rapid growth on follow-up imaging studies (Fig. 2). An 
abdominal magnetic resonance image without contrast (to 
assess renal insufficiency) in 2014 showed an 8.4-cm right 
adrenal mass demonstrating intermediate heterogenous 
T2 signal most suggestive of soft-tissue signal intensity. 
In-phase and opposed-phase T1 images and fat-suppressed 
sequences confirmed both microscopic and macroscopic 
fat, respectively (Fig. 3). In 2015, computed tomography 
(CT) scans without contrast showed progressive enlarge-
ment to 9.6 cm and 10.1 cm with gross macroscopic fat. 
Splenic and osseous changes consistent with known SCD 
were also seen.
 A follow-up CT scan in 2018 showed the right adre-
nal mass now measuring 12.3 cm in greatest dimension; 
however, it also showed significantly more macroscopic 
fat (Fig. 4). Again, splenic and osseous changes related to 
SCD were demonstrated.
 The patient’s initial laboratory investigations were 
unremarkable. Hemoglobin was 13.1 g/dL (reference range 
is 13.7 to 17.5 g/dL), white blood cell count was 7.4 103/µL 
(reference range is 3.7 to 10.3 103/µL), platelet count was 
113 103/µL (reference range is 155 to 369 103/µL), mean 
corpuscular volume was 78 fL (reference range is 79 to 98 
fL), and mean corpuscular hemoglobin was 28 pg (refer-
ence range is 26 to 32 pg). 
 His biochemical investigations were also normal. 
Normetanephrine was 0.35 nmol/L (reference range is <0.9 
nmol/L), metanephrine was <0.2 nmol/L (reference range 
is <0.5 nmol/L), serum bilirubin was 1.7 mg/dL (reference 
range is 0.2 to 1.1 mg/dL), blood urea was 8 mg/dL (refer-
ence range is 7 to 21 mg/dL), serum creatinine was 1.0 mg/
dL (reference range is 0.8 to 1.3 mg/dL), total calcium was 
8.8 mg/dL (reference range is 8.9 to 10.2 mg/dL), fasting 
blood glucose was 401 mg/dL (reference range is 74 to 99 
mg/dL), alanine aminotransferase was 64 IU/dL (reference 
range is 11 to 41 IU/dL), and aspartate aminotransferase 
was 43 IU/dL (reference range is 12 to 40 IU/dL). A low-
dose dexamethasone suppression test showed appropriate 
suppression with a morning cortisol level of 1.7 µg/dL 
(reference range is <1.8 µg/dL). Fig. 1. Sagittal ultrasound image of the right suprarenal region demon-strates a diffusely echogenic right adrenal mass.
Fig. 2. Graph of tumor size (A) in August 2001, August 2011, January 2015, July 2015, and March 2018 measured on axial computed tomography imag-
es. Multiple axial computed tomography images (B) showing growth of the fat-containing right adrenal mass over time (white arrows).
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Fig. 3. (A) Axial T1-weighted magnetic resonance image (MRI) with fat saturation pre-contrast. Axial in-phase (B) and out-
of-phase (C) T1 MRIs show a right adrenal mass with a decrease in signal intensity on the out-of-phase image and regions of 
India ink artifact indicating the presence of intracellular and extracellular lipids. (D) Axial T2-weighted MRI with fat satura-
tion. (E) Axial T2 single-shot fast spin echo MRI shows an 8.4-cm mass with intermediate T2 hyperintense mass involving 
the right adrenal gland. Axial diffusion-weighted images with low b-value (F), high b-value (G), and corresponding apparent 
diffusion coefficient (H) demonstrating mild restricted diffusion. MRI = magnetic resonance image.
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hematology for appropriate SCD management and had an 




 The presence of macroscopic fat within an adrenal 
mass at imaging is suggestive of AM in most cases (1,2). 
However, mass-forming extramedullary hematopoiesis 
(EMH) is another type of fat-containing mass that should 
be considered in the differential diagnosis in patients 
with hematologic disorders. Myelolipoma of the adrenal 
gland is a benign tumor that consists of mature fat cells 
and hematopoietic cells such as myeloid tissue. AMs are 
asymptomatic in most cases but can cause abdominal pain, 
flank pain, mass-effect, or retroperitoneal hemorrhage in 
large sizes. These tumors are incidentally found in the 
course of abdominal cross-sectional imaging evaluation or 
at autopsy (1-3).
 EMH is a physiological response secondary to insuf-
ficient blood cell production and bone marrow function 
(4-6). EMH can be seen in hematologic diseases such 
as hemoglobinopathies, myeloproliferative disorders, 
lymphomas, leukemia, and hemolytic anemias (4,5). EMH 
commonly occurs outside of the bone marrow in the reticu-
loendothelial system such as the spleen and liver, but can 
rarely be seen in organs such as brain, adrenals, pleura, 
bowel, and breast (7-10). EMH in the adrenals is rare and 
is thought to be a compensatory mechanism secondary to 
altered hematopoiesis in patients with hemolytic disorders 
(8). A few cases of EMH involving the adrenal glands have 
been reported in patients with SCD, beta-thalassemia, and 
hereditary spherocytosis (5,7-9).
 The pathogenesis of AM in SCD is unknown. One of 
the proposed theories is that increased erythropoietin levels 
Fig. 4. Noncontrast axial computed tomography image showing a 
large heterogenous adrenal mass containing macroscopic fat. The mass 
measured 12.3 × 12.1 × 9.3 cm.
 The patient was readmitted to the hospital in 2019 
for a sickle cell crisis with a hemoglobin of 8.6 g/dL 
(reference range is 13.7 to 17.5 g/dL) and platelet count 
of 83 103/µL (reference range is 155 to 369 103/µL). An 
uncomplicated laparoscopic hand-assisted right adrenal-
ectomy was performed with an uneventful postoperative 
course. The specimen measured 17.0 × 14.5 × 8.0 cm. 
Scant adrenal tissue was identified on the surface of the 
mass which measured 3.7 × 0.7 cm. The definitive diagno-
sis was confirmed with histopathology and revealed AM. 
The patient has been non-compliant with following up with 
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in chronic hemolytic disease might stimulate metaplasia of 
embryonic stem cells to myeloid tissue (11). Multiple cases 
of AM have been reported in patients with thalassemia 
and SCD (12-14). There is no documented association 
between hemolytic diseases and AM. However, it is possi-
ble that the hematopoietic stress in chronic anemia stim-
ulates the metaplasia of adrenal stromal cells to myeloid 
tissue and results in the rapid growth of the tumor in this 
population (15).
 AMs and mass-forming EMH share common char-
acteristics on imaging and histology. On imaging, AM 
is confidently diagnosed when an encapsulated mass 
originating from the adrenal gland contains fatty tissue. 
Adrenal EMH, often similar in appearance, appears as 
a well-defined mass composed of fat and variable inter-
nal soft-tissue. On histology, they are both composed of 
mature adipose tissue and variable amounts of hemato-
poietic elements (2,3,16). Genetic evaluation to confirm 
clonal origin of myelolipomas has been reported and may 
be helpful to distinguish EMH when clinical history is 
confounding (16,17). Therefore, EMH maybe underdiag-
nosed in this patient population, as genetic evaluation is 
not routinely performed.
 Management of fatty adrenal masses is dependent on 
the tumor size, symptoms, and suspicion for malignancy. 
There have been multiple studies on treatment guidelines. 
Yalagachin and Bhat (18) suggested that surgery is indicat-
ed in functional tumors or tumors ≥6 cm. Smaller tumors 
with benign imaging characteristics can be managed 
conservatively. Bokhari et al (19) concluded that patients 
with symptomatic tumors or tumors >7 cm can undergo 
elective surgical resection. Laparoscopic is the standard 
surgical approach due to minimal postoperative compli-
cations, blood loss, and shorter hospital length of stay. 
However, open resection might be a better option for lesions 
≥10 cm (20).
 In this case, the patient was clinically asymptomatic 
and his tumor was metabolically inactive. However, due 
to the size of the mass and its significant growth over 
time, surgical excision was performed and the tumor was 
successfully removed by right laparoscopic hand-assist-
ed adrenalectomy. Pathological studies of the specimen 
confirmed the diagnosis of AM. Genetic testing of the 




 Rare cases of rapidly enlarging AM can be seen 
in patients with hematologic disorders. AM are benign 
neoplasms that can be difficult to differentiate from EMH. 
Percutaneous needle biopsy might be indicated if the diag-
nosis remains unclear. Management of AM depends on the 
size and symptoms. Surgical excision is recommended in 
symptomatic patients or lesions ≥10 cm (18). Smaller or 
asymptomatic lesions should be managed conservatively. 
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